Bin Zheng, PhD, who specializes in targeted therapies and immunotherapy, was appointed director of melanoma research in the Department of Biomedical Sciences at Los Angeles-based Cedars-Sinai Cancer.
In his new role, Dr. Zheng will be tasked with developing and leading a comprehensive translational and basic science research program for melanoma by working closely with the organization's surgical and medical oncology leadership team, according to an April 16 news release from Cedars-Sinai.
Dr. Zheng's research focuses on how the metabolism of melanoma cancer cells and the tumor microenvironment influence resistance mechanisms to existing immunotherapies, such as checkpoint inhibitors, which fight cancer with a patient's immune system.